Democritus University of Thrace (DUTH)
Μελέτη επιγενετικών και φαρμακοεπιγενετικών βιοδεικτών στο σακχαρώδη Διαβήτη τύπου ΙΙ
Abstract
dc:descriptionT2DM is characterized by inadequate pancreatic β-cell function, insulin resistance and chronic inflammation, which progressively lead to the occurrence of hyperglycemia. Pharmacotherapy of chronic illnesses such as T2DM should be effective, with minimal side effects and affordable. Thus, early detection of ongoing β-cell death would allow timely interventions when significant functionable β-cells are still present. The pancreatic β-cell epigenome plays a key role in the pathophysiology of T2DM, in particular changes in DNA methylation patterns highlighting the functional role of epigenetic changes and their potential clinical value. A suggested valuable biomaterial is ccfDNA, which is thought to reflect reliably the epigenetic events occurring in the affected tissue. The purpose of this research was to introduce minimally invasive epigenetic and pharmacoepigenetic biomarkers in T2DM. Specifically, the ultimate aim of the epigenetic study was to investigate the structure of ccfDNA in T2DM towards the development and validation of a pancreatic β-cell specific signature based on DNA methylation. In the pharmacoepigenetic study the aim was to investigate whether the development of hypoglycemia under sulphonylurea treatment is influenced by epigenetic factors, independently or in combination with genetic factors. In the epigenetic study, initially, the levels of total ccfDNA were quantified by Qubit assay. It was observed that median levels of ccfDNA did not differ between patients and healthy controls. The analysis of fragment size distribution of ccfDNA by capillary electrophoresis revealed that peaks around ~160bp were detected more frequently in T2DM patients, indicating cellular release during apoptosis possibly due to the on-going death of pancreatic β-cells. Also, the analysis of global DNA methylation load of ccfDNA was assessed for the first time, by Raman spectroscopy. In patients with T2DM, it was observed that ccfDNA samples had a higher peak corresponding to the structure of methyl groups than healthy controls, indicating that the T2DM patient ccfDNA is more methylated than healthy controls. Furthermore, the DNA methylation status of INS, IAPP, GCK, KCNJ11 and ABCC8 genes was investigated by SYBR-based qMSP assays in ccfDNA. In almost all studied genes unmethylated alleles (suggesting pancreatic β-cell origin) were statistically significantly elevated in patients with T2DM versus healthy controls, possibly due to the ongoing death of pancreatic β-cells. The analysis of the combination of all five genes using logistic regression, led to a model/classifier with very high accuracy, sensitivity and specificity as a biomarker of T2DM, which may be a useful minimally invasive tool in the clinical management of T2DM and of DM in general. In order to validate the classifier, we used an independent validation study group, in which we analyzed the DNA methylation profile of the five pancreatic β-cell genes and we applied their levels of unmethylated alleles into the developed classifier. The performance of the model/classifier have been reduced, probably due to the small number of individuals in this study group and the non-specific sample collection and storage with the optimized protocols for ccfDNA studies.In the pharmacoepigenetic study, the DNA methylation profile of the KCNJ11 and ABCC8 genes promoters was analyzed by SYBR-based qMSP assays in gDNA from peripheral blood leukocytes of T2DM patients under sulphonylureas treatment. Our results suggested that only methylation of the ABCC8 gene promoter can affect the occurrence of hypoglycemic events in T2DM patients treated with sulfonylureas regardless of the patient's KCNJ11 E23K genotype. However, the presence of DNA methylation in at least one promoter (KCNJ11 or ABCC8) was significantly associated with non-hypoglycemic patients who are carriers of the KCNJ11 EK allele, highlighting that the KCNJ11 E23K polymorphism in association with either of the two genes' DNA methylation may have protective role against sulfonylurea-induced hypoglycemia.Our results enriched our knowledge of the ccfDNA biology in T2DM, but also, they revealed new ccfDNA parameters of potential clinical value. Our study was the first to use experimental liquid biopsy data in combination with DNA methylation to develop a pancreatic β-cell signature with great clinical value. Validation in a larger number of T2DM patient samples and also in prospectively collected specimens may further highlight the clinical value of the signature in early diagnosis, screening and monitoring of this important disease. Also, this study was the first to evaluate the impact of DNA methylation on drug target gene promoters associated with sulphonylurea-induced hypoglycemia during T2DM treatment. The results of this study contribute further to the pharmacoepigenetic knowledge of DM pharmacotherapy and pave the way for similar studies in larger populations with increased clinical value.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Karaglani, Makrina
- Καραγλάνη, Μακρίνα
Subjects
dc:subject × 16Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45252